Alexandros Sagkriotis

If you want to help create a future where: 1️⃣ people with rare diseases have faster diagnoses and better treatment options, and 2️⃣ innovators find a coordinated, sector-wide approach to get new tests and treatments to market, and help them stay there ➡️ read our latest report with Genetic Alliance UK: https://lnkd.in/e8iPr7Xi It recommends 10 actions that government, regulators, industry, academia, funders, clinicians, and patient groups can take to #ChangeTheRareFuture for those living with rare conditions.

119

🎙️ On the latest episode of The Respiratory Catalyst Podcast from Health Data Research UK (HDR UK), hear from UK Biobank Deputy Chief Scientist Dr Adam Lewandowski. Hosted by Prof Jenni Quint, together they discuss how UK Biobank is used by researchers, particularly those exploring respiratory disease and Adam explains how researchers can securely access the data they need for their particular studies. ✅ Listen here: https://ow.ly/coxc50X2OsM

106

NHS Wales has launched its new Healthcare Science Framework, mapping career pathways and opportunities in the profession. The IBMS contributed to the development of the Pathology and Genomics pathway to ensure it reflects the realities of biomedical science in Wales. You can read more about the framework and how it supports biomedical scientists here: https://bit.ly/4fHgkBi

55

ISPOR announced details for its #ISPOREurope 2025. The conference is the leading global conference in Europe for health economics and outcomes research (HEOR) and is scheduled for 9-12 November in Glasglow, Scotland, UK with the theme, “Powering Value and Access Through Patient-Centered Collaboration.” #ISPORNews #HEOR Learn more: https://ow.ly/jgFA50X9ZHQ

56

“It has the potential to stop or slow Parkinson’s.” NRG Therapeutics has secured an impressive £50 million to advance their drug, NRG5051, into clinical trials for people with Parkinson’s. The Parkinson’s UK Virtual Biotech originally invested £1 million in 2019, and is now working in partnership with the Parkinson's Foundation. Dr Lynsey Bilsland is here to tell you more about the drug, how we remain an active founding investor and the next steps.

219

10 Comments

Today we’re pleased to share our Clinical Academics Summit statement, signed by over 40 organisations 🤝 An alarming decline in clinical academic posts threatens the UK’s ability to develop new treatments and remain a global leader in health research ⚠️ Clinical academics are vital in connecting research and patient care – shaping research priorities through frontline experience and bringing new scientific discoveries straight to patients 🧑‍⚕️ ✨ Earlier this year, we convened leaders from universities, research funders, industry partners, the NHS and Government at a summit to commit to action to help reverse this trend. The statement of ambition and intent seeks to address the OSCHR reports’ recommendation to increase the number of permanent clinical academic posts, year-on-year. Our summit attendees committed to five priorities: 1️⃣ Raise awareness of the benefits and opportunities in clinical academia 2️⃣ Prioritise funding for new posts 3️⃣ Champion clinical research as central to care delivery 4️⃣ Build local partnerships across academia, industry, funders and the NHS 5️⃣ Tackle barriers faced by underrepresented groups including nurses, midwives, allied health professionals, ethnic minorities and women 📖 Read the full statement: https://lnkd.in/eU4PiVbS #ClinicalAcademics #HealthResearch #MedicalResearch

121

3 Comments